Analyst firms · UBS · DVA
UBS DVA price target and rating history
DaVita Inc. (DVA) · Health Care
UBS rates DaVita Inc. (DVA) Buy with a $142 price target, as of its latest action on Aug 7, 2023. It has published 3 rating actions on DVA since August 2022, including 1 upgrade and 1 downgrade.
- Current rating
- Buy
- Price target
- $142
- Median target, all firms
- Too few
- Actions on DVA
- 3
UBS price target on DVA
Every UBS rating on DVA
- Aug 7, 2023
- Oct 31, 2022
- Aug 19, 2022
How other firms rate DVA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| TD Cowen | Buy | $220 | Aug 7, 2026 |
| Deutsche Bank | Buy | $220 | May 6, 2026 |
Questions about UBS and DVA
- What is UBS's price target for DVA?
- UBS's latest stated price target for DaVita Inc. (DVA) is $142, from its action on Aug 7, 2023.
- What is UBS's rating on DVA?
- UBS rates DVA Buy, a bullish rating, as of Aug 7, 2023.
- When did UBS last change its view on DVA?
- On Aug 7, 2023, UBS upgrades to Buy from Neutral, price target $100 to $142.
More DVA rating histories
All UBS ratingsDVA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.